Exclusive: In lieu of an IPO in rocky biotech market, Apnimed lines up $80M from existing investors for two PhIII trials

With the biotech market where it is, beset by sinking stock prices for startups that went public during a pandemic boon and unkind to newer …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex­clu­sive: In lieu of an IPO in rocky biotech mar­ket, Ap­n­imed lines up $80M from ex­ist­ing in­vestors for two PhI­II tri­als